Evidence map›Paper›PMID 40545747›Full record

ReviewJournal of diabetes2025

Management Guidelines for Diabetic Patients With Hypertension.

Weiqing Wang, Qin Wan, Suijun Wang, Guang Ning, Yufang Bi, Lianyong Liu, Yan Liu, Yu Liu, Xiaoying Li, Tingzhi Li and 16 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Costs of pharmacological treatment in hypertension and type 2 diabetes mellitus].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Observational
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Weiqing WangDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-0197-3106
Qin WanDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Suijun WangDepartment of Endocrinology, Shanghai, China.
Guang NingDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yufang BiDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lianyong LiuDepartment of Endocrinology, Punan Hospital of Pudong New District, Shanghai, China.
Yan LiuDepartment of Endocrinology, Third People's Hospital of Datong, Datong, China.ORCID https://orcid.org/0009-0007-4149-1036
Yu LiuDepartment of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-6012-5305
Xiaoying LiDepartment of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China.
Tingzhi LiDepartment of Endocrinology, Loudi First People's Hospital, Loudi, China.
Xueyi WuDepartment of Endocrinology, The Second People's Hospital of Guiyang, Guiyang, China.
Shengli WuEndocrine and Metabolism Center, Karamay Hospital of Traditional Chinese and Western medicine (Karamay People's Hospital), Karamay, China.
Yubo ShaDepartment of Endocrine and Metabolic Diseases, The First People's Hospital of Dali, Dali, China.
Yifei ZhangDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-0272-0602
Rongyue ChenDepartment of Endocrinology, Xuchang Hongyue Diabetes Hospital, Xuchang, China.
Hongting ZhengDepartment of Endocrinology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-6930-0103
Dong ZhaoCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
Ling HuThe Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, China.
Peng DuanDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, China.
Xinguo HouDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, China.
Guoyue YuanDepartment of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yu XuDepartment of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-1045-8309
Shan HuangDepartment of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiqiang KangDepartment of Endocrinology, Zhengzhou Central Hospital, Zhengzhou, China.
Qijuan DongDepartment of Endocrinology and Metabolism, People's Hospital of Zhengzhou, Zhengzhou, China.
Huanfeng PanDepartment of Endocrinology, Jilin People's Hospital, Jilin, China.

Funding

Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0508100
6 · The paper itself

Abstract

Hypertension is one of the most common comorbidities associated with diabetes. The standardized diagnosis and treatment of hypertension in diabetic patients, along with achieving blood pressure targets, is of great significance for reducing long-term complications, extending lifespan, and improving quality of life. Recent high-quality multicenter large-sample intervention studies have provided important evidence-based grounds for setting blood pressure targets in diabetic patients. Therefore, based on a comprehensive summary of important domestic and international research literature, and in combination with clinical practice experience, this management guideline is now formulated.

Indexed as

Antihypertensive AgentsDiabetes ComplicationsDiabetes MellitusHypertensionBlood PressureHumansPractice Guidelines as TopicAntihypertensive Agentsdiabetes mellitushypertensionmedicationrisk factortarget

Identifiers

PMID40545747
PMCPMC12183327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.